PDT Partners LLC Buys New Position in Tyra Biosciences, Inc. $TYRA

PDT Partners LLC purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 25,684 shares of the company’s stock, valued at approximately $820,000.

Other large investors have also modified their holdings of the company. Walleye Capital LLC acquired a new stake in Tyra Biosciences in the 2nd quarter worth approximately $11,112,000. Seven Fleet Capital Management LP increased its stake in Tyra Biosciences by 149.6% during the 1st quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company’s stock valued at $7,606,000 after purchasing an additional 119,025 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Tyra Biosciences by 448.0% in the first quarter. Bank of America Corp DE now owns 209,922 shares of the company’s stock worth $8,040,000 after buying an additional 171,612 shares during the last quarter. 5AM Venture Management LLC lifted its stake in shares of Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after buying an additional 90,000 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Tyra Biosciences during the first quarter worth $24,222,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TYRA. Jefferies Financial Group reissued a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a research report on Wednesday, August 5th. JonesTrading began coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Wolfe Research initiated coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Bank of America raised their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.90.

Tyra Biosciences Stock Down 0.3%

TYRA stock opened at $26.13 on Friday. Tyra Biosciences, Inc. has a 52 week low of $11.70 and a 52 week high of $40.65. The firm has a 50-day simple moving average of $29.58 and a 200-day simple moving average of $32.22. The stock has a market capitalization of $1.56 billion, a P/E ratio of -10.89 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.